A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505127-31-00

Acronym

IGM-2323-102

Enrollment

Registered

2023-11-30

Start date

2024-02-08

Completion date

2025-02-10

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Poland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026